

**CLASS: A**

**PROTOCOLS USED IN: Respiratory Distress**

**PHARMACOLOGY AND ACTIONS:**

Ipratropium is an atropine derivative used for inhalation therapy. For severe asthma, Ipratropium taken in addition to a short acting beta agonist (such as Albuterol) can provide greater bronchodilation and clinical benefit than the beta agonist alone. It has no anti-inflammatory effects and does not decrease bronchial hyper-responsiveness.

**INDICATIONS:**

As a supplement to Albuterol in patients with asthma and COPD.

**CONTRAINDICATIONS:**

**Do not use in patients with severe glaucoma.**

**PRECAUTIONS:**

Ipratropium in the meter dose inhaler and auto-inhaler formulations should not be administered to individuals allergic to soy lecithin or related food products (e.g. soy beans, peanuts). The nebulized formulation may be administered to these patients.

**SIDE EFFECTS AND NOTES:**

- A. Dry mouth.
- B. Pharyngeal irritation.
- C. Increased intra-ocular pressure in glaucoma patients.

**ADULT DOSING:**

**Asthma/ COPD -**  
0.5 mg via nebulizer.

**PEDIATRIC DOSING:**

**Same as adult dosing**